Related references
Note: Only part of the references are listed.Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia
Marta Martin-Izquierdo et al.
HAEMATOLOGICA (2021)
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes
Matteo Bersanelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
How we manage adults with myelodysplastic syndrome
Pierre Fenaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Integrating the Immunome in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design
Susann Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
Luca Malcovati et al.
BLOOD (2020)
Genetics of progression from MDS to secondary leukemia
Andrew J. Menssen et al.
BLOOD (2020)
Novel Prognostic Models for Myelodysplastic Syndromes
Jacob Shreve et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
Guillermo Montalban-Bravo et al.
BLOOD ADVANCES (2020)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Detlef Haase et al.
LEUKEMIA (2019)
BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes
Nour Abuhadra et al.
LEUKEMIA & LYMPHOMA (2019)
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Laurence Lode et al.
HAEMATOLOGICA (2018)
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
Laurence Lode et al.
HAEMATOLOGICA (2018)
An increased percentage of myeloid CD34+bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups
T. -H. Chen-Liang et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2018)
Consequences of mutant TET2 on clonality and subclonal hierarchy
Cassandra M. Hirsch et al.
LEUKEMIA (2018)
Mutation Clearance after Transplantation for Myelodysplastic Syndrome
E. J. Duncavage et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes
Aziz Nazha et al.
BLOOD (2018)
Dynamics of clonal evolution in myelodysplastic syndromes
Hideki Makishima et al.
NATURE GENETICS (2017)
Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
Manja Meggendorfer et al.
HAEMATOLOGICA (2017)
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
A. Nazha et al.
LEUKEMIA (2017)
Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis
Zhen Guo et al.
LEUKEMIA RESEARCH (2017)
Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
Manja Meggendorfer et al.
HAEMATOLOGICA (2017)
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
Xavier Calvo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
D. A. Sallman et al.
LEUKEMIA (2016)
Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression
A. Pellagatti et al.
LEUKEMIA (2016)
Time-dependent changes in mortality and transformation risk in MDS
Michael Pfeilstoecker et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
Aziz Nazha et al.
HAEMATOLOGICA (2016)
Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis
Fernando Ramos et al.
ONCOTARGET (2016)
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
Aziz Nazha et al.
HAEMATOLOGICA (2016)
Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis
Michael I. Carr et al.
TRANSLATIONAL CANCER RESEARCH (2016)
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Luca Malcovati et al.
BLOOD (2015)
The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts
Min-Gu Kang et al.
BMC CANCER (2015)
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
M. G. Della Porta et al.
LEUKEMIA (2015)
SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS
D. Inoue et al.
LEUKEMIA (2015)
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution
Chien-Chin Lin et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia
Luca Malcovati et al.
BLOOD (2014)
Genetic alterations of the cohesin complex genes in myeloid malignancies
Swapna Thota et al.
BLOOD (2014)
Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations
Tung-Liang Lin et al.
HAEMATOLOGICA (2014)
Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems
Bin Fu et al.
MODERN PATHOLOGY (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders
Frederik Damm et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression
Marta Fernandez-Mercado et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
Austin G. Kulasekararaj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes
D. M. Murphy et al.
LEUKEMIA (2013)
SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias
F. Damm et al.
LEUKEMIA (2013)
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group
Arjan A. van de Loosdrecht et al.
LEUKEMIA & LYMPHOMA (2013)
Somatic SETBP1 mutations in myeloid malignancies
Hideki Makishima et al.
NATURE GENETICS (2013)
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
Rami S. Komrokji et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival
Carlos Santamaria et al.
ANNALS OF HEMATOLOGY (2012)
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes
Felicitas Thol et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion
Amel Sebaa et al.
GENES CHROMOSOMES & CANCER (2012)
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Julie Schanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
Luca Malcovati et al.
BLOOD (2011)
Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes
Felicitas Thol et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A High Occurrence of Acquisition and/or Expansion of C-CBL Mutant Clones in the Progression of High-Risk Myelodysplastic Syndrome to Acute Myeloid Leukemia
Hsiao-Wen Kao et al.
NEOPLASIA (2011)
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value
Alexander E. Smith et al.
BLOOD (2010)
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
Felicitas Thol et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
Olivier Kosmider et al.
BLOOD (2009)
Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes
Matteo Giovanni Della Porta et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian et al.
CANCER (2008)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Luca Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia
H Harada et al.
BLOOD (2004)
Share Paper
